Clinical Trials Logo

Stage III Follicular Lymphoma clinical trials

View clinical trials related to Stage III Follicular Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT03600363 Recruiting - Clinical trials for Lymphoma, Large B-Cell, Diffuse

A Clinical Trial of Metformin in the Maintenance of Non-Hodgkin's Lymphoma Patients

Start date: September 1, 2018
Phase: Phase 2
Study type: Interventional

The study is to evaluate the therapeutic effect of metformin as a maintenance therapy in high risk patients with complete remission of diffuse large B lymphoma / stage III follicular lymphoma after chemotherapy in the initial R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone, plus the monoclonal antibody rituximab) regimen

NCT ID: NCT02652910 Recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma

MeCAR
Start date: December 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this clinical trial is to study how approaches for manufacturing chimeric antigen receptor (CAR)-modified T (CAR-T) cells affect their in vivo persistence and therapeutic efficacy against B lymphoma. Recently, cancer immunotherapy, treatments aiming to arm patients with immunity specifically against cancer cells, has emerged as a promising therapeutic strategy. Among the many emerging immunotherapeutic approaches, clinical trials utilizing CARs against B cell malignancies have demonstrated remarkable potential. CARs combine the variable region of an antibody with T-cell signaling moieties to confer T-cell activation with the targeting specificity of an antibody. Thus, CARs are not MHC-restricted so they are not vulnerable to MHC down regulation by tumors. However, defined by the activation and contraction program of their mother cells, the persistency and function of CAR-T cells are also restricted by the protocol of manufacturing. Previous clinical studies largely utilized interleukin-2 (IL-2) for the ex vivo expansion of CAR-T cells, which preferentially generate CAR-T cells with characteristics of terminally differentiated effector cells. Our preliminary data indicated that two common gamma chain cytokines, IL-7 and IL-15, can help to selectively expand CAR-T cells with various memory phenotypes. CAR-T Cells prepared under this condition resulted in improved therapeutic efficacy in preclinical animal models. This clinical investigation is to test a hypothesis whether IL-7/IL-15-programmed anti-CD19 CAR-T cells persist longer in lymphoma patients after infusion and whether the persistency of CAR-T cells can lead to improved anti-lymphoma efficacy.